Cancer recurs in up to 40% of patients following surgery for high-risk, locoregional renal cell carcinoma (RCC). To date, little progress has been made in identifying systemic adjuvant treatment options to reduce the mortality risk after surgery for high-risk RCC. Several randomized trials exploring the efficacy of adjuvant targeted therapies in the postoperative setting have recently reported results. We examine these trials to assess the contemporary role of targeted therapy following surgery in high-risk RCC and briefly consider trials that are currently accruing with a focus on immunotherapy agents in the adjuvant setting. PATIENT SUMMARY: Kidney cancer often recurs despite initial surgery in patients with high-risk tumors. So far, adding systemic treatments such as targeted therapies after surgery has not resulted in improved survival outcomes. Future studies that include immunotherapy after surgery to reduce the risk of recurrence in patients with high-risk disease are eagerly anticipated.
European urology focus. 2019 Apr 08 [Epub ahead of print]
Douglas G Ridyard, Dylan M Buller, Benjamin T Ristau
Division of Urology, UConn Health, Farmington, CT, USA., University of Connecticut School of Medicine, Farmington, CT, USA., Division of Urology, UConn Health, Farmington, CT, USA. Electronic address: .